Loading...

Michael Ballard, PhD

TitlePostdoc
SchoolUCSF School of Medicine
DepartmentNeurology
Address675 Nelson Rising Lane
San Francisco CA 94158
EmailMichael.Ballard@ucsf.edu
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    UCSF / UC BerkeleyPostdoctoral Studies2016fMRI Neuroimaging & Cognitive Neuroscience
    UCLAPostdoctoral Studies2014PET Neuroimaging
    University of ChicagoPh.D.2012Neurobiology
    Emory UniversityB.S. 2001Neuroscience & Behavioral Biology
    Collapse Awards and Honors
    UCLA2013 - 2014NIDA T32 Translational Neuroscience of Drug Abuse trainee
    College on Problems of Drug Dependence2013Frontiers in Addiction Research Early Career Investigator Travel Award
    Behavior, Biology & Chemistry2012Translational Research in Addiction Predoctoral Travel Award
    Society for Neuroscience2012Federation of European Neuroscience Societies Forum Travel Award
    University of Chicago2011Biological Sciences Division Travel Award
    National Institute on Drug Abuse2010College on Problems of Drug Dependence Director’s Travel Award
    University of Chicago2009 - 2012Training Program in Pathobiology and Translational Neuroscience
    University of Chicago2009Junior Student Award
    National Institute on Drug Abuse2009American Psychological Association Early Career Investigator Travel Award
    University of Chicago2007 - 2009NIDA T32 Drug Abuse Research trainee

    Collapse Overview 
    Collapse Overview
    Dr. Ballard is a Postdoctoral Scholar at UCSF, Research Affiliate at UC Berkeley, and Research Health Science Specialist at the VA Northern California Health Care System. His current research uses functional MRI brain imaging to investigate the capacity of dopamine-enhancing drugs to improve emotional regulation and self-control in veterans who have mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD). Prior to joining Dr. Andy Kayser's laboratory at UCSF, Dr. Ballard was a NIDA T32-funded Postdoctoral Fellow in Dr. Edythe London's Laboratory of Molecular Neuroimaging at UCLA and the VA Greater Los Angeles Healthcare System, where he used positron emission tomography (PET) brain imaging to study the role of dopamine receptors in maladaptive decision-making and poor self-control among methamphetamine abusers. Dr. Ballard completed his PhD in Neurobiology at the University of Chicago, as a NIDA T32- and F31-funded Fellow in Dr. Harriet de Wit's Human Behavioral Pharmacology Laboratory. There, his thesis work focused on the acute effects of amphetamines and THC on emotional processing and memory in healthy human volunteers. Before entering graduate school, Dr. Ballard worked in preclinical drug discovery at Abbott Laboratories (now Abbvie) for several years, using rodent models to identify potential novel psychiatric medications. As an undergraduate at Emory University, he studied opioid withdrawal in rodents under Dr. Stephen Holtzman.


    Collapse Research 
    Collapse Research Activities and Funding
    The effect of amphetamine on the different stages of emotional memory
    NIH F31DA030863May 1, 2011 - Apr 30, 2013
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Ballard M, Dean AC, Mandelkern MA, London ED. Striatal Dopamine D2/D3 Receptor Availability Is Associated with Executive Function in Healthy Controls but Not Methamphetamine Users. PLoS One. 2015; 10(12):e0143510. PMID: 26657223.
      View in: PubMed
    2. Ballard M, Weafer J, Gallo DA, de Wit H. Effects of acute methamphetamine on emotional memory formation in humans: encoding vs consolidation. PLoS One. 2015; 10(2):e0117062. PMID: 25679982; PMCID: PMC4332474.
    3. Ballard M, Mandelkern MA, Monterosso JR, Hsu E, Robertson CL, Ishibashi K, Dean AC, London ED. Low Dopamine D2/D3 Receptor Availability is Associated with Steep Discounting of Delayed Rewards in Methamphetamine Dependence. Int J Neuropsychopharmacol. 2015 May; 18(7):pyu119. PMID: 25603861; PMCID: PMC4540098.
    4. London ED, Kohno M, Morales AM, Ballard M. Chronic methamphetamine abuse and corticostriatal deficits revealed by neuroimaging. Brain Res. 2015 Dec 2; 1628(Pt A):174-85. PMID: 25451127.
      View in: PubMed
    5. Ballard M, Gallo DA, de Wit H. Amphetamine increases errors during episodic memory retrieval. J Clin Psychopharmacol. 2014 Feb; 34(1):85-92. PMID: 24135845; PMCID: PMC4244906.
    6. Ballard M, Gallo DA, de Wit H. Pre-encoding administration of amphetamine or THC preferentially modulates emotional memory in humans. Psychopharmacology (Berl). 2013 Apr; 226(3):515-29. PMID: 23224510; PMCID: PMC3595317.
    7. Ballard M, Bedi G, de Wit H. Effects of delta-9-tetrahydrocannabinol on evaluation of emotional images. J Psychopharmacol. 2012 Oct; 26(10):1289-98. PMID: 22585232; PMCID: PMC3664416.
    8. Ballard M, Gallo DA, de Wit H. Psychoactive drugs and false memory: comparison of dextroamphetamine and d-9-tetrahydrocannabinol on false recognition. Psychopharmacology (Berl). 2012 Jan; 219(1):15-24. PMID: 21647577; PMCID: PMC4244903.
    9. Ballard M, de Wit H. Combined effects of acute, very-low-dose ethanol and delta(9)-tetrahydrocannabinol in healthy human volunteers. Pharmacol Biochem Behav. 2011 Feb; 97(4):627-31. PMID: 21110996; PMCID: PMC3018238.
    10. Zhang M, Ballard M, Basso AM, Bratcher N, Browman KE, Curzon P, Konno R, Meyer AH, Rueter LE. Behavioral characterization of a mutant mouse strain lacking D-amino acid oxidase activity. Behav Brain Res. 2011 Feb 2; 217(1):81-7. PMID: 20933022.
      View in: PubMed
    11. White DA, Ballard M, Harmon AC, Holtzman SG. Acute delta- and kappa-opioid agonist pretreatment potentiates opioid antagonist-induced suppression of water consumption. Brain Res Bull. 2008 Aug 15; 76(6):597-604. PMID: 18598850; PMCID: PMC2504860.
    12. Zhang M, Ballard M, Unger LV, Haupt A, Gross G, Decker MW, Drescher KU, Rueter LE. Effects of antipsychotics and selective D3 antagonists on PPI deficits induced by PD 128907 and apomorphine. Behav Brain Res. 2007 Aug 22; 182(1):1-11. PMID: 17570538.
      View in: PubMed
    13. Ballard M, Basso AM, Gallagher KB, Browman KE, Fox GB, Drescher KU, Gross G, Decker MW, Rueter LE, Zhang M. The drug-induced helplessness test: an animal assay for assessing behavioral despair in response to neuroleptic treatment. Psychopharmacology (Berl). 2007 Jan; 190(1):1-11. PMID: 17093979.
      View in: PubMed
    14. Zhang M, Ballard M, Kohlhaas KL, Browman KE, Jongen-Rêlo AL, Unger LV, Fox GB, Gross G, Decker MW, Drescher KU, Rueter LE. Effect of dopamine D3 antagonists on PPI in DBA/2J mice or PPI deficit induced by neonatal ventral hippocampal lesions in rats. Neuropsychopharmacology. 2006 Jul; 31(7):1382-92. PMID: 16395300.
      View in: PubMed
    15. Zhang M, Ballard M, Pan L, Roberts S, Faghih R, Cowart M, Esbenshade TA, Fox GB, Decker MW, Hancock AA, Rueter LE. Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs. Brain Res. 2005 May 31; 1045(1-2):142-9. PMID: 15910772.
      View in: PubMed
    16. Fox GB, Esbenshade TA, Pan JB, Browman KE, Zhang M, Ballard M, Radek RJ, Miner H, Bitner RS, Krueger KM, Yao BB, Faghih R, Rueter LE, Komater VA, Drescher KU, Buckley MJ, Sullivan JP, Cowart MD, Decker MW, Hancock AA. Selective H3 receptor (H3R) blockade: broad efficacy in cognition and schizophrenia. Inflamm Res. 2005 Apr; 54 Suppl 1:S23-4. PMID: 15928819.
      View in: PubMed
    17. Fox GB, Esbenshade TA, Pan JB, Radek RJ, Krueger KM, Yao BB, Browman KE, Buckley MJ, Ballard M, Komater VA, Miner H, Zhang M, Faghih R, Rueter LE, Bitner RS, Drescher KU, Wetter J, Marsh K, Lemaire M, Porsolt RD, Bennani YL, Sullivan JP, Cowart MD, Decker MW, Hancock AA. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. J Pharmacol Exp Ther. 2005 Apr; 313(1):176-90. PMID: 15608077.
      View in: PubMed
    18. Rueter LE, Ballard M, Gallagher KB, Basso AM, Curzon P, Kohlhaas KL. Chronic low dose risperidone and clozapine alleviate positive but not negative symptoms in the rat neonatal ventral hippocampal lesion model of schizophrenia. Psychopharmacology (Berl). 2004 Nov; 176(3-4):312-9. PMID: 15179541.
      View in: PubMed
    Michael's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Related Authors
    People who share related concepts with this person.
    _
    Back to TOP